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UDP-galactofuranose (UDP-Galf) is a substrate
for two types of enzymes, UDP-galactopyranose
mutase and galactofuranosyltransferases, which are
present in many pathogenic organisms but absent
from mammals. In particular, these enzymes are
involved in the biosynthesis of cell wall galactan,
a polymer essential for the survival of the causative
agent of tuberculosis, Mycobacterium tuberculosis.
We describe here the synthesis of derivatives of
UDP-Galfmodified at C-5 and C-6 using a chemoen-
zymatic route. In cell-free assays, these compounds
prevented the formation of mycobacterial galactan,
via the production of short ‘‘dead-end’’ intermediates
resulting from their incorporation into the growing
oligosaccharide chain. Modified UDP-furanoses thus
constitute novel probes for the study of the two
classes of enzymes involved in mycobacterial galac-
tan assembly, and studies with these compounds
may ultimately facilitate the future development of
new therapeutic agents against tuberculosis.
INTRODUCTION
The development of new drugs against tuberculosis (TB) still
presents a major challenge (Balganesh et al., 2008) because of
the widespread distribution of the disease, the occurrence of
multidrug and extensively drug-resistant strains of Mycobacte-
rium tuberculosis (Chan and Iseman, 2008), and the deadly
combination of HIV and TB infections (Corbett et al., 2003). In
this area, a major target for drug development is the mycobacte-
rial cell wall, and its biosynthesis has received increasing study in
the past several years (Barry et al., 2007). At the core of this intri-
cate structure is the mycolyl-arabinogalactan-peptidoglycan
(mAGP) complex, which is composed of covalently linked pep-
tides, heteropolymeric carbohydrates (peptidoglycan and arabi-1356 Chemistry & Biology 17, 1356–1366, December 22, 2010 ª2010nogalactan), and highly hydrophobic mycolic acids. The mAGP
is a well validated target for drug development, and some of
the most effective antituberculotics prevent the formation of
this component of the M. tuberculosis cell wall (Barry et al.,
2007). The extremely impermeable cell wall efficiently protects
pathogenic mycobacteria against multiple stress factors faced
during the course of infection; at the same time, it constitutes a
rather vulnerable structure, a true Achilles heel of the bacterium.
Among the four first-line anti-TB drugs, two impinge on the
assembly of distinct structures of the mAGP. Isoniazid inhibits
the production of mycolic acids (Takayama et al., 1972; Winder
et al., 1971), and ethambutol blocks the generation of a complete
arabinan domain (Mikusova et al., 1995; Takayama and Kilburn,
1989). The galactan portion of the mAGP represents yet another,
and so far underexplored, potential target for anti-TB drug devel-
opment because of its essential role for the viability of mycobac-
teria (Pan et al., 2001) and xenobiotic status of its building block,
galactofuranose (Galf), in the human host (Pedersen and Turco,
2003).
In a series of investigations performed by Brennan, McNeil,
and colleagues, the structure of the mAGP galactan has been
established as a linear chain of about 30 alternating (1/5)-linked
and (1/6)-linked b-D-Galf residues (Besra et al., 1995; Daffe
et al., 1993; McNeil et al., 1987). The galactan region is linked
to C-6 of N-glycolyl/N-acetyl muramic acid residues (Mahapatra
et al., 2005a; Mahapatra et al., 2005b) of peptidoglycan via
a linker disaccharide unit, a-L-Rhap-(1/3)-D-GlcpNAc-1-P
(Daffe et al., 1990; McNeil et al., 1990). The arabinan portions
of the mAGP are, in turn, attached to O-5 of the (1/6)-linked
Galf residues close to the reducing end of the galactofuran
(Alderwick et al., 2005) in the form of three highly branched
chains, each consisting of 31 Araf residues (Bhamidi et al., 2008).
The biosynthesis of the galactan component of the mAGP
has, to a large extent, been elucidated (Belanova et al., 2008).
As illustrated in Figure 1, its assembly begins on decaprenyl-P-
P-GlcpNAc-Rhap (GL-2), which is formed by the sequential
action of two enzymes, a GlcNAc-1-phosphate-transferase
(Rv1302) and a rhamnosyltransferase (Rv3265c) (Mikusova
et al., 1996; Mills et al., 2004). We have shown that only two gal-
actofuranosyltransferases, GlfT1 (Rv3782) and GlfT2 (Rv3808c),Elsevier Ltd All rights reserved
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Figure 1. Metabolic Pathway for Biosynthesis of Mycobacterial Galactan
The pathway can be followed by in vitro reaction using mycobacterial enzyme fractions and UDP-[14C] Galp as a tracer. Glycolipids GL-1 to GL-5 are extracted
into CHCl3–CH3OH (2:1), and lipid-linked galactan polymer into more polar solvents.
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Inhibition of Mycobacterial Galactan Biosynthesisappear to account for full galactan synthesis (Belanova et al.,
2008). The bifunctional enzyme GlfT1 attaches the first two
Galf residues to the GL-2 intermediate forming both Galf-
b-(1/4)-Rhap and Galf-b-(1/5)-Galf glycosidic bonds (Bela-
nova et al., 2008;Mikusova et al., 2006). The product of this reac-
tion, decaprenyl-P-P-GlcpNAc-Rhap-Galf-Galf (GL-4), serves
as the direct substrate for the full galactan polymerization cata-
lyzed by GlfT2, another dual-acting enzyme with both b-(1/5)Chemistry & Biology 17, 1356–136and b-(1/6) activity (Kremer et al., 2001; Mikusova et al.,
2000; Rose et al., 2006). Galactofuranose residues for trans-
ferase reactions are donated by UDP-a-D-Galf (1) (Figure 2),
which is produced from UDP-a-D-Galp by the action of UDP-
galactopyranose mutase (Glf, Rv3809c) (Weston et al., 1997;
Soltero-Higgin et al., 2004).
Despite the information presented above, questions remain
about the specificity of GlfT1 and GlfT2, and more detailed6, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1357
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Figure 2. Structure of UDP-Galf (1) and
Analogs 2–5 Modified at C-5 or C-6
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Inhibition of Mycobacterial Galactan Biosynthesisinvestigations of these enzymes has been hampered by the lack
of access to their donor and acceptor substrates. However,
recently we have published procedures for the preparation of
a panel of synthetic analogs that correspond to GL-2 and
GL-3, the natural acceptor substrates for GlfT1, as well as
analogs of GL-4 and GL-5, substrates for GlfT2 (Completo and
Lowary, 2008). In addition, recent advances in the preparation
of the donor substrate, UDP-a-D-Galf (Peltier et al., 2007;
Timmons et al., 2008; Rose et al., 2008), have paved the way
for further examination of these galactofuranosyltransferases,
which will lead to better understanding of these intriguing bifunc-
tional enzymes.
Synthetic substrate analogs, particularly deoxygenated and
fluorinated compounds (Pongdee and Liu, 2004), are valuable
tools for probing the mechanism of enzyme-catalyzed reactions.
Many are good enzyme inhibitors, some of which have been
developed into clinically useful chemotherapeutic agents (Pong-
dee and Liu, 2004). Recently, we have prepared a series of
synthetic fluorinated and deoxygenated analogs of UDP-a-D-
Galf (1) that are subtly modified in the two-carbon exocyclic
side chain (Figure 2) (Peltier et al., 2007; Timmons et al., 2008).
In place of the hydroxymethyl group at the C-5 position of (1),
UDP-6F-a-D-Galf (2) bears a fluoromethyl function; the fluorine
atom is nearly isosteric to a hydroxyl group but acts only as
hydrogen bond acceptor, rather than as both a hydrogen bond
donor and acceptor. UDP-b-L-Araf (3) lacks the C-5 hydroxy-
methyl altogether. UDP-6-deoxy-a-D-Galf (4) carries a hydro-
phobic methyl group in place of the hydroxymethyl substituent,
and UDP-5-deoxy-a-D-Galf (UDP-5-deoxy-b-L-arabino-hexo-
furanose, 5) lacks the polar hydroxyl group at C-5; both are ex-
pected to have altered hydrogen-bonding capabilities compared
with the parent substrate. Moreover, as depicted in Figure 1,
these analogs may be able to interfere with the elongation of
the lipid-linked galactan polymer, through their incorporation
into the growing chain by GlfT1 and GlfT2. In the present study,1358 Chemistry & Biology 17, 1356–1366, December 22, 2010 ª2010 Elsevier Ltd All rights rewe investigated the impact of UDP-Galf
analogs 2–5 on the biosynthesis of
mycobacterial galactan. A better under-
standing of this process could lead to tar-
geting of this crucial structure of the
mycobacterial cell wall for the develop-
ment of new drugs against TB.
RESULTS
Chemical Synthesis of UDP-Galf
AnalogsModified at C-5 or C-6 (2–5)
The 6-deoxy-6-fluoro-UDP-Galf deriva-
tive 2 and UDP-L-Araf 3 were prepared
as previously described (Peltier et al.,
2007; Peltier et al., 2008b).
The synthesis of 4 (Figure 3) started
from the knownmethyl glycoside 6 (Com-
pleto and Lowary, 2008; Pathak et al.,1999), which was converted in three steps and excellent overall
yield into alcohol 7. Next, treatment of 7with triphenylphosphine
and iodine at room temperature in the presence of imidazole
(Garegg and Samuelsson, 1980) gave primary iodide 8 in a
96% yield. Subsequent cleavage of the carbon-iodine bond by
catalytic hydrogenation at elevated pressure (15 psi) afforded
a 90% yield of 9. Treatment of 9 with 44% HBr in HOAc led to
the corresponding glycosyl bromide, which, following its forma-
tion, was immediately reacted with dibenzyl phosphate, thus
yielding 10 as the pure a-isomer in 59% yield. The modest yield
of the reaction is ascribed to the hydrolysis of the less stable
b-anomer upon chromatography, which has been reported in
the preparation of a-galactofuranosyl phosphate (de Lederk-
remer et al., 1994). The two benzyl groups in 10 were cleaved
by catalytic hydrogenation and the three benzoyl groups were
then removed by treatment with 5:2:1 methanol-triethylamine-
water to give 6-deoxy-a-D-galactofuranosyl phosphate 11 in
50% overall yield from 10.
With 11 in hand, it was converted to the corresponding sugar
nucleotide 4 using an enzymatic approach, as has been previ-
ously reported for the preparation of UDP-Galf by Field and
coworkers (Errey et al., 2004). Thus, incubation of 11 with UDP-
glucose and UTP in the presence of three enzymes—a promis-
cuous galactose-1-phosphate uridyltranserase, UDP-glucose
pyrophorylase and inorganic pyrophosphatase—yielded 4 in
70% overall yield (Rose et al., 2008). The anomeric proton in
the 1H NMR spectrum of 4 appeared as a doublet of doublets
(3JH1,H2 = 5.9 Hz and
3JH1,Pa = 4.2 Hz), and in the
1H-decoupled
31P NMR spectrum, two doublets (J = 20.7 Hz) were present at
dP = 10.2 and 10.6 ppm, arising from the two coupled phos-
phorous atoms of the sugar nucleotide moiety. These data are
in good agreement with those reported previously for the parent
sugar nucleotide, UDP-Galf (Koplin et al., 1997).
The preparation of 5 (Figure 3) was achieved starting from
primary alcohol 7 by treatment with silver oxide in DMF, whichserved
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Figure 3. Synthesis of 4 and 5
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Inhibition of Mycobacterial Galactan Biosynthesisinduced a benzoyl migration reaction that gave secondary
alcohol 12 in a 60% yield. Reaction of 12 with triphenylphos-
phine and iodine, as was done for the preparation of 8,
provided the secondary iodide 13 in excellent (96%) yield.
Although in the formation of 8, the reaction proceeded easily
at room temperature, in the case of 13, it was necessary to
heat the reaction mixture at 90C. To reduce 13, catalytic
hydrogenation was investigated. Using conditions that had
worked well in the synthesis of the 6-deoxy derivative, none
of the anticipated product was obtained. Even increasing the
hydrogen pressure to 45 psi (3 atm) was unsuccessful. Radical
deoxygenation was therefore employed to cleave the carbon-
iodine bond (Patroni et al., 1986). Thus, 13 was heated at reflux
with tin hydride and AIBN to afford 14 in 98% yield. As
described for the preparation of 10, deoxy-glycoside 14 was
converted into a glycosyl bromide by reaction with 44% HBr
in HOAc, and this product was treated with dibenzyl phosphate
and triethylamine to afford 5-deoxy-b-L-arabino-hexofurano-
side phosphate 15 in 48% overall yield. The product was de-
protected in two steps to yield 16 in 53% yield. The same enzy-
matic synthesis employed in the preparation of 4 was used to
convert 16 into the target compound 5 in a 71% yield. Proof
of the structure was obtained from NMR spectroscopy: H-1
appears as a doublet of doublet (3JH1,H2 = 5.9 Hz and
3JH1,Pa = 4.2 Hz) in the
1H NMR spectrum, and the proton-Chemistry & Biology 17, 1356–136decoupled 13P NMR spectrum shows two doublets (7.6 and
9.1 ppm, 3JP,P = 20.7 Hz).
Mycobacterial GalactanBiogenesis Is Severely Inhibited
by UDP-Galf Analogs 2–5 Modified at C-5 or C-6
Previously, we have shown that mycobacterial galactan build-up
can be monitored in a cell-free reaction containing mycobacte-
rial membrane and cell wall fractions, and UDP-[14C]Galp (Miku-
sova et al., 2000). The lipid carrier for galactan assembly, decap-
renyl phosphate, was supplied by the crude enzymatically active
membranes and cell wall. The reaction mixture was supple-
mented with UDP-GlcpNAc and dTDP-Rhap for in situ formation
of the GlfT1 substrate, decaprenyl-P-P-GlcpNAc-Rhap (GL-2),
and occasionally by recombinant Glf for more efficient conver-
sion of UDP-Galp into UDP-Galf. In this experiment, production
of three distinct glycolipids, GL-3, GL-4, and GL-5, is observed,
which can be extracted with CHCl3–CH3OH (2:1). Further extrac-
tion of the reaction mixture with more polar solvents (Mikusova
et al., 2000) results in the isolation of a heterogeneous population
of metabolic intermediates, termed lipid-linked galactan poly-
mer. We have shown that these compounds contain GlcNAc,
Rha, and the expected (1/5)-linked and (1/6)-linked Galf resi-
dues (Mikusova et al., 2000).
We have tested the effect of analogs 2–5 (Figure 2) on
galactan build-up in the above-described system, along with6, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1359
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Figure 4. Effects of UDP-Galf Analogs on the Cell-Free Production
of GL-3 to GL-5 and Lipid-Linked Galactan Polymer
TLC profile of CHCl3–CH3OH (2:1) fraction; bands were visualized by autoradi-
ography. Quantification of the lipid-linked galactan polymer was performed by
scintillation counting.
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Inhibition of Mycobacterial Galactan BiosynthesisUMP-6F-a-D-Galf and UDP-a-L-Araf (the 1,2-trans isomer of 3)
(Peltier et al., 2008b), which we expected would serve as nega-
tive controls (Figure 4). Each compound was added to the
reactionmixtures at a concentration of 100 mg/ml and, after incu-
bation, the products were extracted as described in the Experi-
mental Procedures. TLC analysis of the CHCl3–CH3OH (2:1)
fraction revealed that the addition of UDP-b-L-Araf (3) and
UDP-5-deoxy-a-D-Galf (5) resulted in the complete inhibition of
galactose-containing glycolipids, whereas significant reduction
of galactolipid production, with particular absence of GL5, was
observed in case of UDP-6F-a-D-Galf (2) and UDP-6-deoxy-a-
D-Galf (4). The synthesis of the lipid-linked galactan polymer,
obtained by extraction of the incubation mixture with CHCl3–
CH3OH–H2O (10:10:3) and ‘‘E-soak,’’ was almost completely
inhibited in the presence of the tested analogs 2–5. As expected,
addition of UMP-6F-a-D-Galf and UDP-a-L-Araf did not have
any effect on elongation of the galactan chain.UDP-Galf Analogs 2–5 Serve as Substrates of GlfT1
Such a severe inhibition of galactan build-up by the UDP-Galf
analogs could be explained in two ways. One possibility is thatUDP- Galf (1) 
UDP- 6FGalf (2) 
UDP- LAraf (3) 
+ 
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Figure 5. Effects of 2–5 on the Activity of Recombinant GlfT1
TLC profile of CHCl3–CH3OH (2:1) fraction; the bands were visualized by autoradio
concentration.
1360 Chemistry & Biology 17, 1356–1366, December 22, 2010 ª2010the compounds are inhibiting one or more of the three enzymes
involved in galactan assembly: GlfT1, GlfT2, or Glf. The second
possibility is that the compounds are serving as efficient sub-
strates for these enzymes, resulting in competition between
the natural substrate and the synthetic analog. Incorporation of
nonradioactive substrates into the galactan products would
appear as a decrease in radioactivity in the bands corresponding
to the individual galactolipids.
We examined these possibilities by direct investigation of the
effects of 2–5 on GlfT1. These compounds were included in the
assay for examination of GlfT1 activity, as recently described
elsewhere (Belanova et al., 2008). In our previous work, we ex-
ploited UDP-Galp and Glf as a source of UDP-Galf (1) for the
reaction catalyzed by GlfT1. However, synthetic 1 can also be
used. Thus, the reaction mixture contained the crude lysate of
Escherichia coli cells expressing recombinant GlfT1 fromMyco-
bacterium smegmatis, radiolabeled GL-1/2 mixture, in which
GL-2 served as a natural acceptor substrate, as well as the
natural donor substrate UDP-Galf (1) and/or its synthetic ana-
logs. Reaction products were analyzed by TLC (Figure 5).
From these experiments it is clear that analogs 2–5 serve as
substrates for GlfT1, giving rise to glycolipids migrating on TLC
slightly higher than GL-3 or GL-4 because of the more hydro-
phobic nature of the incorporated analogs (Figure 5, lanes
3–6). It appears that GlfT1 incorporates two residues from
UDP-b-L-Araf (3) (Figure 5, lane 4), and only one residue from
other three tested compounds. It can be expected that, particu-
larly in case of the 5-deoxy analog (5), chain termination should
occur at the first GlfT1 reaction. Transfer of the 5-deoxy-Galf
residue to GL-2 produces a modified GL-3 analog, lacking the
requisite hydroxyl group for chain extension by the second
transferase activity of GlfT1.
When the tested compounds were included in the reaction
mixture containing an equimolar concentration of the natural
donor substrate 1, we observed synthesis of the natural product
of the reaction, GL-4, as well as another compound, which we
propose corresponds to modified GL-4, containing both Galf
and its modified counterpart (Figure 5, lanes 7–14). These prod-
ucts were formed regardless of the manner in which UDP-Galf
was provided to the enzyme, either directly in the form of 1    7        8       9     10      11     12     13     14 
e 
+++ +
in the form of UDP-Galp and mutase  
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+++ +
graphy. Natural substrate and synthetic analogs were used in the same 200 mM
Elsevier Ltd All rights reserved
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Figure 6. Dose Response for the Addition of 2–5 into the In Vitro Reactions for Mycobacterial Galactan Build-Up
TLC of the [14C]Galf-containing glycolipids was produced in the reaction mixtures with decreasing concentration of 2–5. Inhibition of galactan polymer production
was evaluated by scintillation counting.
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Inhibition of Mycobacterial Galactan Biosynthesis(Figure 5, lanes 7–10), or indirectly from UDP-Galp and Glf (Fig-
ure 5, lanes 11–14). These results indicate that none of the
compounds 2–5 appreciably inhibit the mutase enzyme that
produces UDP-Galf.
Incorporation of UDP-Galf Analogs into GL-4 Results
in the Production of ‘‘Dead-End’’ Intermediates
The finding that 3 and 5 are GlfT1 substrates came as rather
surprising, because lack of radiolabeled galactolipid products
in the initial experiments gave the impression of the efficient
inhibition of the metabolic utilization of the radioactive UDP-
Galp by these analogs (Figure 4, lanes 5 and 7). However, as
mentioned above, we could rule out inhibition of Glf, because
when UDP-Galp and Glf were used as source of UDP-Galf (1),
the production of natural GL-4 and modified GL-4 was observed
in the presence of the analog, confirming efficient in situ produc-
tion of UDP-Galf (Figure 5, lanes 11–14).
One explanation for this apparent contradiction would be if 3
and 5 had a rather high affinity for GlfT1, resulting in the prefer-
ential production of modified glycolipids GL-3 and/or GL-4, con-
taining solely the modified residues, which would not be radio-
labeled in the experiment using UDP-[14C]Galp. To test this
hypothesis, we used the above assay for a competition study
with varying concentrations of all four compounds 2–5 (Figure 6).
It is clear from the TLC profile of CHCl3–CH3OH (2:1) extracts
that, indeed, a ten-fold lowering of the concentrations of UDP-
b-L-Araf (3) or UDP-5-deoxy-a-D-Galf (5) in the reactionmixtures
from the originally used 100 mg/ml led to less efficient competi-
tion of the natural substrate UDP-Galf (1) with the analogs, result-
ing in the synthesis of radiolabeled compounds (Figure 6, lanes 7
and 15).
Of all the compounds, the UDP-5-deoxy-a-D-Galf (5) was the
most potent competitor with 1 in the reaction catalyzed by GlfT1,
and UDP-6-deoxy-a-D-Galf (4) was comparable to UDP-6F-a-
D-Galf (2). In the presence of about 15-fold higher amount of
the latter two analogs in the reaction mixtures compared to the
radioactive natural substrate, efficient production of radiola-
beled modified glycolipids is still observed, confirming incorpo-
ration of much less abundant radioactive natural substrate in
the reaction mixture to the products (Figure 6, lanes 2 and 10).
This is in contrast with the results for 5 (Figure 6, lane 14), which
appears to be used preferentially as a substrate by GlfT1 underChemistry & Biology 17, 1356–136these conditions. In the dose response experiment performed
with compounds 2–5, less than equimolar concentration of the
analogs (9 mM) compared to the radioactive natural substrate
(11 mM) was sufficient to achieve about 50%–80% inhibition of
galactan synthesis, respectively (Figure 6, lanes 4, 8, 12, and
16). We thus propose that in the presence of 2–5 modified
‘‘dead-end’’ glycolipid intermediates are formed (Figure 7A)
leading to truncation of galactan polymerization.
To test this hypothesis, we made use of a synthetic GL-2
analog, octyl disaccharide 17 (Completo and Lowary, 2008) (Fig-
ure 7B), which hadpreviously been shown to be aGlfT1 substrate
(Belanova et al., 2008). Disaccharide 17 and 5 were first incu-
bated in the presence of GlfT1 and then the reaction mixture
was analyzed by LC-MS. As predicted, a product corresponding
to trisaccharide 18 (Calculatedm/z = 648.3202 [M + Na+], Found
m/z = 648.3191) was formed (data not shown). Similar reaction
of 17 with the 6-deoxy analog 4 gave a trisaccharide product
19 (Calculated 648.3202 [M + Na+], Found m/z = 648.3194).
Effects of UDP-Galf Analogs 2–5 on GlfT2
Although the work outlined above suggests that 2–5 exert their
effect on galactan polymerization via GlfT1, the overall inhibition
of galactan synthesis in the presence of these compounds could
be further strengthened by inhibition of GlfT2. We have therefore
examined the effect of these compounds on recombinant GlfT2
using a recently described spectrophotometric assay (Rose
et al., 2008). Using a trisaccharide acceptor substrate, and
a 2 mM concentration of the synthetic analogs and 0.5 mM
concentration of UDP-Galf, we have observed 25% inhibition
of GlfT2 activity for both UDP-6F-a-D-Galf (2) and UDP-5-
deoxy-a-D-Galf (5), and 32% inhibition in case of UDP-6-
deoxy-a-D-Galf (4). The 6-deoxy-derivative also serves as
a substrate for GlfT2 achieving 50% of the activity of the natural
substrate at 2 mM. UDP-b-L-Araf (3) served as a very weak
substrate of the enzyme (3% of the natural substrate); it did
not act as an inhibitor of GlfT2.
DISCUSSION
The method described here for the preparation of 4 and 5makes
use of a chemoenzymatic approach that has previously been
employed for the preparation of UDP-Galf (Rose et al., 2008;6, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1361
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(A) ‘‘Dead-end’’ galactolipid intermediates inhibit
further elongation of mycobacterial galactofuran.
(B) Synthetic GL-2 analog 17 and the reaction
products produced upon its reaction with either 4
or 5 in the presence of GlfT1.
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Inhibition of Mycobacterial Galactan BiosynthesisErrey et al., 2004). The advantage of this approach over a purely
chemical approach is that the formation of the sugar nucleotide
from the corresponding Galf-1-phosphate derivative (i.e., 11 and
16) proceeds more efficiently and in higher yield. An obvious
limitation of this approach is that the enzyme may not recognize
all modified Galf-1-phosphate analogs of interest. Nevertheless,
the successful preparation of 4 and 5, as well as the preparation
of 2 and 3 reported earlier (Peltier et al., 2008b), demonstrates
that the key uridyl transferase will tolerate modification of the
exocyclic diol moiety, albeit with varying degree of efficiency.
The straightforward availability of UDP-Galf synthetic analogs
has prompted us to test their effects on mycobacterial galactan
biosynthesis. Our data confirm that 2–5 in a concentration of
100 mg/ml almost completely abolish cell-free production of
the galactan polymer. To the best of our knowledge, this is the
first report of compounds that so severely inhibit galactan
biosynthesis.
Three enzymes are involved in mycobacterial galactan
assembly, Glf and the glycosyltransferases GlfT1 and GlfT2.
Glf has received the most attention to date (Eppe et al., 2009;
Yuan et al., 2008; Barlow and Blanchard, 2000; Zhang and Liu,
2001a; Richards and Lowary, 2009), and a number of inhibitors
of this enzyme have been identified (Kovensky et al., 1999; Liau-
tard et al., 2008; Itoh et al., 2007). Most notable are a family of
derivatives, some of which have also been demonstrated to1362 Chemistry & Biology 17, 1356–1366, December 22, 2010 ª2010 Elsevier Ltd All rights reinhibit mycobacterial growth in the same
range as the clinically used antitubercu-
losis agents ethambutol and rifampicin
(Dykhuizen et al., 2008).
Over the past 10 years, several reports
on the preparation of compounds that
could serve as probes and potential inhib-
itors of GlfT1 and GlfT2 have been pub-
lished, but the focus has been primarily
on acceptor analogs. Among them, b-D-
Galf-(1/4)-a-L-Rhap and b-(1/5)- and
b-(1/6)-linked octyl Galf disaccharides
were shown to serve as substrates for
these enzymes and showed moderate
antimycobacterial effects (Pathak et al.,
1999; Pathak et al., 2001). Modest inhibi-
tion of galactosyltransferase activity has
also been reported for analogs of the
arabinogalactan linker disaccharide a-L-
Rhap-(1/3)-a-D-GlcpNAc (Wen et al.,
2003). More recent investigations have
focused on the synthesis and use of Galf
oligomers for probing the specificity of
GlfT1 and GlfT2 in vitro (Belanova et al.,2008; Completo and Lowary, 2008; Gandolfi-Donadio et al.,
2003).
Despite the focus on acceptor derivatives, some work has
addressed the preparation of donor analogs as probes of GlfT1
and GlfT2. For example, Fleet and coworkers studied the effects
of Galf iminosugar analogs on galactan biosynthesis and found
about 60% inhibition at a concentration of 200 mg/ml, but this
was attributed to inhibition of Glf, which was needed in the assay
to generate the donor species (Lee et al., 1997). In other studies,
Thomas and coworkers extended the investigation of imino-
sugars to develop inhibitors based on a proposed model of the
transition state of the transferase reaction. These investigations
led to the identification of the first donor-based inhibitor of
galactosyltransferase activity (presumably GlfT2) in M. smeg-
matis with an IC50 value of 4.8 mM (Cren et al., 2004). Finally,
a recent investigation by Bugg and coworkers described the
synthesis and evaluation of uridine-linked transition state mimics
of the GlfT2 transfer reaction, which inhibited the enzyme,
although the level of inhibition was not quantified (Trunkfield
et al., 2010).
In the present report, we show that selected UDP-Galf analogs
modified at C-5 or C-6 inhibit galactan assembly in anM. smeg-
matis cell-free assay by 50% or more at a concentration of only
9 mM (5 mg/ml). The incorporation of these analogs into the
growing galactan chain by GlfT1, leading to modified dead-endserved
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nism by which polymer production is halted. However, at the
same time, UDP-6-deoxy-a-D-Galf (4) showed activity as the
substrate of GlfT2 and thus this enzyme may also introduce
6-deoxy-Galf residues into the polymer chain leading to similar
‘‘dead-end’’ intermediates. In addition, compounds 2, 4, and 5
served also as weak inhibitors of GlfT2. Earlier work has shown
that UDP-6F-a-D-Galf (2) and UDP-b-L-Araf (3) serve as sub-
strates for Glf from E. coli (Eppe et al., 2009; Zhang and Liu,
2001b); thus, in principle, these compounds can compete
with the natural substrate, in turn inhibiting the efficiency of gal-
actan polymerization. However, again this pathway also appears
to be comparatively minor as experiments studying the effect
of 3 and 5 on GL-4 formation showed that comparable results
were obtained either when synthetic UDP-Galf was used in the
reaction, or when this intermediate was produced in situ using
UDP-Galp and Glf.
Although sugar nucleotides such as 2–5 are expected to have
limited potential as lead drug candidates as a result of their
poor cell penetration, these species nevertheless have the
potential to be very useful tools in probing galactan assembly
in mycobacteria. For example, because GlfT1 catalyzes two
sequential glycosyl transfer reactions, the product of the first
glycosylation (GL-3) is a substrate for the second transferase
activity leading to the formation of GL-4. As described above,
GlfT1 uses the 5-deoxy-UDP-Galf derivative 5 to generate
a GL-3 derivative that is incapable of being further glycosylated.
Hence, this derivative could prove useful in studies in which it
is desirable to dissect the two different transferase activities of
the enzyme. Analogous investigations with GlfT2 can be envi-
sioned. These compounds will also be useful in studying
the formation of galactofuranose-containing glycoconjugates in
other organisms (Richards and Lowary, 2009; Peltier et al.,
2008a). In addition to various Glfs and galactofuranosyltrans-
ferases from a host of organisms, such investigations could be
extended to a recently identified protein that transfers UDP-
Galf across the Golgi membrane in Aspergillus fumigatus (Engel
et al., 2009).
SIGNIFICANCE
In this article, we report that derivatives of the sugar nucle-
otide UDP-Galf prevent the formation of mycobacterial gal-
actan, an important cell wall component in the organism
that causes the disease tuberculosis, M. tuberculosis. Four
UDP-Galf derivatives, modified at C-5 or C-6 by replacement
of a single hydroxyl group with either hydrogen or fluorine or
through removal of C-6 and the associated hydroxyl group,
were synthesized using a chemoenzymatic route, which
has significant advantages over the chemical synthesis of
these compounds. When evaluated in a cell-free assay at
100 mg/ml, all four compounds abolished the formation of
the full-length galactan polymer. Instead, short ‘‘dead-end’’
intermediates, resulting from incorporation of the modified
carbohydrate residues into the growing carbohydrate chain,
were produced. Thus, these compounds have potential as
chain terminators in studies of galactan biosynthesis in
mycobacteria and as probes of Galf metabolism in other
microorganisms.Chemistry & Biology 17, 1356–136EXPERIMENTAL PROCEDURES
Synthesis of UDP-Galf analogs modified at C-5 or C-6
See Supplemental Experimental Procedures available online.
Preparation of Enzymatically Active Membranes and Cell Envelope
from M. smegmatis
Enzymatically active membranes and cell envelope (wall and membrane) were
prepared essentially as described from M. smegmatis mc2155 grown in
Nutrient Broth (Mikusova et al., 1996). Briefly, cells (10 g) were suspended in
about 40ml of 50mMMOPS buffer (pH 7.9) containing 5mM2-mercaptoetha-
nol and 10 mM MgCl2 (buffer A), subjected to probe sonication, and centri-
fuged at 23,000 3 g for 20 min at 4C. The pellet was resuspended in buffer
A, and Percoll (Amersham Pharmacia Biotech) was added to achieve a 60%
suspension, which was centrifuged at 23,0003 g for 60 min at 4C. The white
upper band was isolated, and Percoll was removed by repeated suspension in
buffer A and centrifugation. The fraction (cell envelope) was resuspended in
buffer A to a protein concentration of 10–20 mg/ml for use. Membranes
were obtained by centrifugation of the 23,000 3 g supernatant at 100,000 3 g
for 2 hr at 4C and suspended in buffer A to give a protein concentration of
20–30 mg/ml.
Preparation of the E. coli Cell Lysate Containing Recombinant GlfT1
for the In Vitro Assays
One hundredmilliliters of culture of the overproducing strain E. coli BL21(DE3)/
pET28a-MSMEG_6367 (Belanova et al., 2008) was grown to OD600 0.6 and
placed on ice for 1 hr. The culture was induced with IPTG at a final concentra-
tion of 0.2 mM, overnight at 16C. The cells were harvested and disintegrated
by probe sonication (10 3 15-s pulses with 40-s cooling intervals between
pulses) in 5-fold excess of buffer A. The cell lysate was cleared by centrifuga-
tion for 20 min at 20,0003 g at 4C, and the supernatant was used as a source
of GlfT1.
Preparation of dTDP-Rha
The synthesis of dTDP-Rha relied on the presence of the full array of the Rha
synthetic enzymes and endogenous cofactors in M. smegmatis and was
prepared from dTDP-Glc using the 100,000 3 g supernatant of disrupted
M. smegmatis as an enzyme source, as described elsewhere (Mikusova
et al., 1996).
Preparation of UDP-Galp Mutase
Histidine-tagged mutase from Klebsiella pneumoniae was purified essentially
as described elsewhere (Beis et al., 2005). The recombinant plasmid for the
preparation of Glf was kindly provided by Prof. David A. R. Sanders from the
University of Saskatchewan, Saskatoon, Canada.
ReactionMixtures, Fractionation, and Analysis of Reaction Products
For the initial establishment of the effects of the synthetic analogs of UDP-Galf
on galactan build-up, we prepared reaction mixtures in which mycobacterial
membrane (0.7 mg of protein) and cell envelope (1 mg of protein) fractions
served as enzyme sources, and UDP-[U-14C]Galp (NEN; 278 mCi/mmol,
0.25 mCi) was used to monitor formation of the galactofuran biosynthetic inter-
mediates. NADH was added to the reaction mixtures in 2.5 mM concentration
to promote the activity of the endogenous mutase, and cold sugar nucleotides
for in situ production of GL-2, UDP-GlcNAc, and TDP-Rha were added in
20 mM concentration. The reactions were supplemented with the UDP-Galf
analogs in concentrations between 1 and 100 mg/ml. Volumes of the reactions
were adjusted to 80 ml with buffer A.
After incubation of the reactionmixtures for 1 hr at 37C, CHCl3–CH3OH (2:1;
1.5 ml) was added, which was left rocking at room temperature for 10 min and
centrifuged (3,000 3 g). The CHCl3-CH3OH phase was removed from the
pellet and treated as described before (Mikusova et al., 2000). To remove
residual radiolabel from the pellet, 50% CH3OH in H2O containing 0.9%
NaCl (0.5 ml) was added, and the mixture was briefly bath-sonicated and
centrifuged at 3,000 3 g. The supernatant was discarded, and the pellet
was further extracted with 50% CH3OH in H2O (0.5 ml) and 100% CH3OH
(0.5 ml), which were also discarded. The washed pellet was extracted with
0.5 ml of the solvent ‘‘TT3’’ (CHCl3–CH3OH–H2O; 10:10:3) (Rush et al., 1993)6, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1363
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finally with 0.5 ml ‘‘E-soak’’ (water–ethanol–diethyl ether–pyridine–concen-
trated ammonium hydroxide; 15:15:5:1:0.017) (Angus and Lester, 1972) to
obtain [14C]Gal-labeled lipid-linked products of greater polarity. To the
CHCl3–CH3OH (2:1) extract, 170 ml of buffer A was added to achieve a biphasic
mixture. The upper aqueous phase was removed and discarded, and the
bottom phase was backwashed with CHCl3–CH3OH–H2O (3:47:48) (Folch
et al., 1957). The backwashed bottom phase was dried under a stream of
N2 at room temperature and redissolved in 50 ml of CHCl3–CH3OH–H2O–
NH4OH (65:25:3.6:0.5). Amounts of the radiolabeled products in the individual
extracts were quantified by scintillation counting. Qualitative analysis of
CHCl3–CH3OH (2:1) extracts was performed by TLC on Silica Gel plates
(Merck) in CHCl3–CH3OH–NH4OH–1 M ammonium acetate–H2O (180:140:
9:9:23), and the radiolabeled lipid bands were visualized by autoradiography.
To examine direct effects of the studied UDP-Galf analogs on the activity of
GlfT1, we have prepared crude GL-1/2 mixture in vitro and used it in the reac-
tion. Reaction mixture for GL-1/2 production contained 9 mg of membranes
from M. smegmatis mc2155, 2 mCi of UDP-[U-14C]GlcNAc (NEN, 288 mCi/
mmol), 20 mMTDP-Rha, and buffer A in a final volume of 640 mL. After 1 hr incu-
bation at 37C, [14C] GlcNAc-radiolabeled glycolipids were extracted with
CHCl3–CH3OH (2:1) and subjected to biphasic Folch wash as described above
(Folch et al., 1957). In vitro reactions using radioactive GL-1/2 as the galactose
acceptors were performed as follows: 3000 dpm of glycolipid preparation
were dried in the stream of N2. This was followed by addition of the enzyme
source [crude lysate of E. coli BL21(DE3)/pET28a-MSMEG_6367 producing
recombinant GlfT1 (Belanova et al., 2008); 0.3 mg of protein] and UDP-Galf
and/or the studied analogs in 200 mM concentration. In cases where UDP-
Galp was used as the source of UDP-Galf, the reaction mixture was supple-
mented with purified Glf and 2.5 mM freshly prepared NADH. Volume of the
reaction was adjusted with buffer A to the final volume 80 mL. The whole
mixture was subsequently briefly bath sonicated. Incubation was performed
for 1 hr at 37C. Extraction of the reaction products and their TLC analysis
was performed as described above.
For LC-MS analysis of the GlfT1 reaction products mixtures containing
3.2 mMGL-2 acceptor analog 17 (Completo and Lowary, 2008), 150 mMdonor
analogs 4 or 5, and 1mgof crudeGlfT1 enzyme (as above) and buffer A in a final
volume of 320 ml were incubated in triplicate for 2 hr at 37C. The reactions
were stopped by addition of 6 ml of CHCl3–CH3OH (2:1), followed by addition
of 680 ml of water to achieve a Folch wash (Folch et al., 1957). The water phase
was backwashed twice with 4ml of CHCl3 and 1ml of CH3OH. Organic phases
from the triplicates were combined and dried under the stream of N2. The
extract was subjected to mild acid hydrolysis in 300 ml of 1-propanol and
600 ml of 20 mMHCl at 60C for 30 min. After cooling, the mixture was neutral-
ized with 30 ml of 0.2 mM NaOH, dried, and subjected to n-butanol–water par-
titioning, as follows: 1.5 ml n-butanol saturated with water and 1.5 ml water
were added to the dried samples, mixed for 20 min, centrifuged and the upper
n-butanol phase was kept. The water phase was extracted two more times
with n-butanol and the combined n-butanol fractions were dried under N2.
This sample was further hydrolyzed in mild alkali conditions with 500 ml of
CHCl3–CH3OH (2:1) and 500 ml 0.2 M NaOH in CH3OH at 37
C for 20 min.
Following neutralization with 2 ml of glacial acetic acid, the reaction products
were again extracted by n-butanol–water partitioning, as described above,
and then dried. Samples were analyzed on Waters Q-TOF Premier LC-MS
system in positive ion mode.
Spectrophotometric Assay for Monitoring GlfT2 Activity
Recombinant GlfT2 was prepared as described elsewhere (Rose et al., 2006).
Spectrophotometric GlfT2 assayswere performed in 384-arraymicrotiter plate
wells, as described elsewhere (Rose et al., 2008). The reaction buffer con-
tained 50 mM MOPS (pH 7.9), 50 mM KCl, 20 mM MgCl2, 1.1 mM NADH,
3.5 mMPEP, 7.5 U pyruvate kinase (PK, EC 2.7.1.40), and 16.8 U lactate dehy-
drogenase (LDH, EC 1.1.1.27). A standard assay reaction contained UDP-Galf
(1) at a final concentration of 0.5 mM and a trisaccharide acceptor substrate,
octyl b-D-galactofuranosyl-(1/5)-b-D-galactofuranosyl-(1/6)-b-D-galacto-
furanoside (Rose et al., 2008) at 2 mM. Each reaction was initiated by the addi-
tion of 0.75 mg GlfT2 to the assay mixture. The final assay volume was 40 mL.
Reactions were monitored at 37C using a Spectra Max 340PC microplate
reader controlled with SOFTmax PRO software (Molecular Devices,1364 Chemistry & Biology 17, 1356–1366, December 22, 2010 ª2010Sunnyvale, CA) in the kinetics read mode, as described elsewhere (Rose
et al., 2008).SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and can be found with this article online at doi:10.1016/j.chembiol.2010.10.
014.
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